MARCKS蛋白是蛋白激酶C (PKC)底物，已知位于几个细胞内信号通路的交汇处，并在细胞生理学中起关键作用。与PKC抑制剂不同，MARCKS靶向药物（BIO-11006）在涉及肺部疾病的临床试验中显示出初步成功。最新的研究调查已经发现两种靶向MARCKS的肽具有多方面的治疗哮喘、癌症、炎症和肺部疾病的意义。本综述文章提供了关于靶向MARCKS的肽用于治疗目的的专利界限和最新发展。在线免费开放获取数据库被用于检索专利信息，而通过PubMed检索研究文章。近年来，关于MARCKS在人类疾病和生理学中引人注目作用的研究结果大大增加。与之相关的专利数量也呈现出类似增长趋势。因此，有必要将这种趋势融合和转化为治疗手段。我们的综述文章概述了这些最新进展，我们相信我们的汇编将引起全球研究人员的兴趣，未来发展针对MARCKS的肽用于人类疾病治疗。

MARCKS protein, a protein kinase C (PKC) substrate, is known to be at the intersection of several intracellular signaling pathways and plays a pivotal role in cellular physiology. Unlike PKC inhibitors, MARCKS-targeting drug (BIO-11006) has shown early success in clinical trials involving lung diseases. Recent research investigations have identified two MARCKS-targeting peptides which possess multifaceted implications against asthma, cancer, inflammation, and lung diseases.This review article provides the patent landscape and recent developments on peptides targeting MARCKS for therapeutic purposes. Online free open-access databases were used to fetch out the patent information, and research articles were fetched using PubMed.Research studies highlighting the intriguing role of MARCKS in human disease and physiology have dramatically increased in recent years. A similar increasing trend in the number of patents has also been observed related to the MARCKS-targeting peptides. Thus, there is a need to amalgamate and translate such a trend into therapeutic intervention. Our review article provides an overview of such recent advances, and we believe that our compilation will fetch the interest of researchers around the globe to develop MARCKS-targeting peptides in future for human diseases.